Table IV.
Recommendations for antithrombotic therapy.
| Author/(Refs.) | Recommendation for anticoagulant therapy |
|---|---|
| Thachil et al (99) | ISTH: Patients admitted to hospital for COVID-19 have no contraindications (hemorrhage or platelet count <25×109/l) should receive prophylactic LMWH. |
| Sardu et al (71) | In absence of contraindications, enoxaparin 40 mg/day is recommended for all patients; enoxaparin 1 mg/kg every 12 h is recommended for those with D-dimer levels >3 µg/ml. |
| Connors and | For obese patients, UFH 7m500 units 3 times a day or 40 mg enoxaparin twice a day are recommended. |
| Levy (100) | Given the short half-life and strong ability to be administered parenterally, LMWH or UFH should be administered to critically ill patients instead of giving direct oral anticoagulants. |
| Klok et al (60) | The prophylactic dose of enoxaparin should be increased from 40 mg daily to 80 mg twice a day for COVID-19 patients admitted to the ICU. |
| Thachil et al (101) | Oral anticoagulants should be used with caution in patients with kidney function deficiency and those taking anti-retroviral drugs. |
| Oudkerk et al (59) | For patients with D-dimer levels <1,000 (ng/ml), prophylactic anticoagulation is recommended. |
| For patients with D-dimer >1,000 (ng/ml) and D-dimer levels increase progressively, therapeutic anticoagulation is recommended. | |
| Bikdeli et al (102) | All hospitalized COVID-19 patients should be evaluated the risk of VTE. In absence of contraindications, all patients should receive prophylactic anticoagulation. |
| All discharged patients should be evaluated the risk of VTE. Patients at risk of VTE should be given prophylactic anticoagulation for 45 days unless thereis a risk of bleeding. | |
| The interaction between antithrombotic drugs and routine COVID-19 drugs should be considered. | |
| The hepatic and renal function, and certain complications, such as DIC and hemorrhage, should be taken into account when undergoing antithrombotic therapy. |
ISTH, International Society on Thrombosis and Hemostasis; LMWH, low molecular weight heparin; UFH, unfractionated heparin; DIC, disseminated intravascular coagulation.